Document is current
Any future updates will be listed below
-
Authors
Carias, Sophia C. https://orcid.org/0009-0009-8974-5896
Buono, Frank D. https://orcid.org/0000-0003-1324-7857
Von Imhof, Liesel
Yelamanchili, Sneha M.
Chan, Hilary
Yohay, Kaleb H. https://orcid.org/0000-0001-5560-3392
Nghiemphu, P. Leia https://orcid.org/0000-0003-4064-6079
Babovic-Vuksanovic, Dusica https://orcid.org/0000-0001-6981-1352
Plotkin, Scott R. https://orcid.org/0000-0002-6109-6419
Merker, Vanessa L. https://orcid.org/0000-0002-4542-5227
-
Funding
Funding for this research was provided by:
Children's Tumor Foundation
- License Information
-
More Information
Article History
Received: 14 July 2025
Accepted: 2 December 2025
First Online: 16 December 2025
Declarations
:
: SCC, FDB, LVI, SMY, HC, and PLN have no relevant financial or non-financial interests to disclose. KHY is a consultant for Alexion Pharmaceuticals and a member of the scientific advisory board of Infixion. DBV is a member of the advisory board of Alexion Pharmaceuticals and SpringWorks Therapeutics. SRP is a consultant for Akouos, co-founder and consultant of NF Therapeutics and NFlection Therapeutics, and a member of the scientific advisory board of SonALAsense. VLM has received consulting income from Alexion Pharmaceuticals.
: All study procedures were reviewed and approved by the Dana Farber/Harvard Cancer Center Institutional Review Board under protocol 19-828 and the Mass General Brigham Institutional Review Board under protocol 2023P003305.
: Informed consent was obtained from all participants included in the study.
